REC 602
Alternative Names: HPV Bivalent (Type 6/11) Vaccine - Jiangsu Recbio Technology; HPV-6/11 vaccine - Jiangsu Recbio Technology; REC-602Latest Information Update: 28 Jun 2024
At a glance
- Originator Jiangsu Recbio Technology
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Genital warts
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Cervical-cancer(Prevention) in China (IM)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Genital warts(Prevention) in China (IM)
- 21 Mar 2022 New profile triggered from 9352572